Aging research is entering a new phase as scientists rethink one of the body's most mysterious cell types: senescent cells, often nicknamed "zombie cells." While these aging cells have long been viewed as harmful drivers of inflammation and disease, new findings suggest the story is far more complicated. In some cases, senescent cells may actually help protect and repair the body.
A new review published May 4, 2026, in Volume 18 of Aging-US explores how cellular senescence shapes aging throughout the body and examines the growing push toward precision anti-aging therapies. The study, titled "Cellular senescence: from pathogenic mechanisms to precision anti-aging interventions," was led by first author Jian Deng and corresponding author Dong Yang from the Department of Targeting Therapy and Immunology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Senescent cells are cells that have permanently stopped dividing. Scientists have traditionally considered them harmful because they accumulate with age and release inflammatory molecules that can damage nearby tissue. These cells have been linked to a wide range of age-related diseases and declining organ function.
However, the review highlights mounting evidence that senescent cells are not universally harmful. Some appear to serve important biological functions, including supporting wound healing, maintaining tissue balance, and helping guide embryonic development.
Researchers describe how senescence develops across many organs, including the liver, lungs, kidneys, heart, brain, skin, and fat tissue. In each of these systems, cells can become senescent due to factors such as oxidative stress, mitochondrial dysfunction, DNA damage, chronic inflammation, metabolic stress, telomere shortening, ultraviolet radiation, and environmental pollution.
The review also explains that senescent cells build up in many specialized cell types, including hepatocytes, endothelial cells, fibroblasts, macrophages, astrocytes, and epithelial cells. Once these cells accumulate, they can interfere with normal tissue structure and contribute to chronic illness.
One of the review's central conclusions is that senescent cells are highly diverse and should not be treated as a single uniform population. Depending on where they are located and how they interact with surrounding tissue, senescent cells can either help or harm the body.
Some senescent cells may limit fibrosis and assist tissue repair, while others appear to fuel chronic inflammation, metabolic disorders, tissue degeneration, and even cancer progression. Because of this complexity, anti-aging researchers are increasingly moving away from strategies that attempt to eliminate all senescent cells.
"Based on these insights, this review summarizes the induction mechanisms of cellular senescence and the subsequent evolution of their functional phenotypes across diverse tissues."
Instead, scientists are now exploring more selective approaches designed to target only the harmful senescent cell populations while preserving beneficial ones.
The review outlines several emerging anti-aging strategies aimed at controlling senescent cells more precisely.
Early senolytic drugs such as dasatinib, quercetin, and fisetin were developed to destroy senescent cells by disrupting the survival pathways that keep them alive. More recent therapies are becoming increasingly sophisticated.
Some researchers are now investigating CAR-T cell immunotherapies that can recognize markers found on senescent cells and selectively remove them. Other approaches involve "senomorphic" therapies, which attempt to reduce the harmful inflammatory signals known as the senescence-associated secretory phenotype (SASP) without killing the cells themselves.
A major concept discussed in the review is "precision geroprotection." This strategy focuses on identifying and eliminating only maladaptive senescent cells while preserving cells that still contribute to tissue repair and stability.
Scientists believe emerging technologies such as single-cell omics, lineage tracing, and spatial profiling may help reveal the distinct subtypes of senescent cells and identify safer therapeutic targets.
Despite growing excitement in the field, researchers caution that major challenges remain before senescence-targeting therapies can be widely used in medicine.
One problem is the lack of highly specific biomarkers that can reliably distinguish harmful senescent cells from beneficial ones. Researchers also face difficulties delivering therapies precisely to target tissues while avoiding unintended damage to healthy organs.
The review warns that broad removal of senescent cells could potentially interfere with tissue repair, immune surveillance, blood vessel stability, and structural integrity in sensitive organs such as the heart, lungs, and brain.
Scientists also still do not fully understand how senescent cell populations change over time in different organs, making it difficult to predict the long-term effects of treatment.
Overall, the review presents a more nuanced understanding of cellular senescence and aging. Rather than viewing all senescent cells as dangerous, researchers increasingly believe the future of anti-aging medicine may depend on distinguishing harmful cells from beneficial ones.
The authors propose a more individualized approach centered on prevention, functional analysis, and precision intervention. As anti-aging science continues to evolve, these strategies could eventually support healthier aging while reducing the risks associated with indiscriminate senescent cell removal.
